M & L Capital Management Ltd Purchases Shares of 5,630 Insulet Corporation $PODD

Key Points

• M & L Capital Management acquired 5,630 shares of Insulet (NASDAQ:PODD) in Q4 valued at about $1.6 million, making it the firm's 20th-largest holding (≈0.3% of its portfolio).
• Other large institutions also initiated or expanded positions—Norges Bank (~$324.7M), Qube Research (~$131.4M), WorldQuant (~$80.1M)—and Squarepoint and Munro each boosted stakes to roughly 227,000 shares (≈$70M each).
• Insulet beat quarterly expectations (EPS $1.55 vs $1.48; revenue $783.8M vs $768.3M, up 31.2% YoY); analysts trimmed targets but the consensus remains a Moderate Buy with an average target of $354.24.

M & L Capital Management Ltd acquired a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,630 shares of the medical instruments supplier's stock, valued at approximately $1,600,000. Insulet comprises about 0.3% of M & L Capital Management Ltd's holdings, making the stock its 20th biggest holding.

Several other hedge funds also recently modified their holdings of the company. Norges Bank bought a new stake in Insulet during the 2nd quarter worth approximately $324,689,000. Qube Research & Technologies Ltd bought a new position in Insulet in the 2nd quarter valued at $131,439,000. Worldquant Millennium Advisors LLC bought a new position in Insulet in the 2nd quarter valued at $80,082,000. Squarepoint Ops LLC boosted its stake in Insulet by 11,905.8% in the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier's stock worth $70,165,000 after purchasing an additional 225,377 shares in the last quarter. Finally, Munro Partners boosted its stake in Insulet by 1,483.0% in the third quarter. Munro Partners now owns 227,240 shares of the medical instruments supplier's stock worth $70,156,000 after purchasing an additional 212,885 shares in the last quarter.

Insider Transactions at Insulet

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director owned 17,483 shares of the company's stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.39% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. The Goldman Sachs Group lowered their target price on Insulet from $363.00 to $326.00 and set a "buy" rating for the company in a research note on Thursday, February 19th. Truist Financial reduced their price target on shares of Insulet from $390.00 to $360.00 and set a "buy" rating on the stock in a research report on Thursday, February 19th. BTIG Research reissued a "buy" rating and set a $380.00 price objective on shares of Insulet in a report on Wednesday, February 18th. Raymond James Financial lowered their price objective on shares of Insulet from $385.00 to $355.00 and set an "outperform" rating for the company in a research report on Thursday, February 19th. Finally, Oppenheimer dropped their target price on shares of Insulet from $365.00 to $300.00 and set an "outperform" rating for the company in a research note on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $354.24.

Insulet Stock Down 0.0%

NASDAQ PODD opened at $227.08 on Tuesday. The stock has a market capitalization of $15.99 billion, a P/E ratio of 64.88, a price-to-earnings-growth ratio of 1.36 and a beta of 1.42. Insulet Corporation has a 52 week low of $216.49 and a 52 week high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock has a fifty day moving average of $251.08 and a 200-day moving average of $291.99.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.15 earnings per share. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.